RecruitingNCT05937828

OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia

"French National Cohort of Patients With Pediatric-onset of Autoimmune Cytopenia (OBS'CEREVANCE Cohort)"


Sponsor

University Hospital, Bordeaux

Enrollment

3,500 participants

Start Date

Sep 1, 2010

Study Type

OBSERVATIONAL

Conditions

Summary

From 2004, OBS'CEREVANCE is a national real-world prospective clinical cohort of patients with auto-immune cytopenia of pediatric-onset : Immune thrombocytopenia (ITP), Autoimmune Hemolytic anemia (AIHA), or Evans syndrome (all bi or tri cytopenias). Thanks to the collaboration of the 30 French pediatric hematologic centers, this cohort supports all of the Rare Disease Centre CEREVANCE (Centre de Référence National des Cytopénies Auto-Immunes de l'Enfant) missions for care, education and research. Specifically, this original unbiased database allows to describe the long-term health of adult patients, to identify the heterogenous genetic underlying pathophysiologic contexts, and to study the benefit-risk balance of treatments, including the growing development of targeted therapies.


Eligibility

Max Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This French study is tracking children with autoimmune blood disorders — conditions where the immune system mistakenly attacks blood cells — to better understand how these diseases develop and respond to treatment over time. **You may be eligible if...** - Your child has been diagnosed with immune thrombocytopenia (ITP, low platelet count), autoimmune hemolytic anemia (AIHA, immune system destroying red blood cells), or Evans Syndrome (both conditions together) - The condition started before age 18 **You may NOT be eligible if...** - The child's legal guardian objects to participation or data collection Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERdata collection

description of the long-term health of adult patients, identification of the heterogenous genetic underlying pathophysiologic contexts, study of the benefit-risk balance of treatments, including the growing development of targeted therapies.


Locations(9)

CHU Amiens Picardie Service d' Onco-Immuno-Hématologie Pédiatrique

Amiens, France

CHU d'Angers Unité d'Hémato-Oncologie Pédiatrique

Angers, France

BESANCON CHU de Besançon Hôpital Jean MINJOZ Unité d'Hémato-Oncologie Pédiatrique, Pédiatrie 1

Besançon, France

CHU de Bordeaux - Unité d'Hématologie et d'Oncologie pédiatrique

Bordeaux, France

CHU BREST Hôpital Morvan Unité d'Onco-Hématologie

Brest, France

CHU de Caen Unité d'Onco-Hématologie

Caen, France

CHU de Clermont Ferrand

Clermont-Ferrand, France

APHP Hôpital Bicêtre Service de Pédiatrie générale

Paris, France

CH de Cornouaille Service de Pédiatrie

Quimper, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05937828


Related Trials